InterMune's ASCENDancy

InterMune Inc. (NASDAQ:ITMN) was rewarded by investors last week after detailed Phase III IPF data suggested its Esbriet pirfenidone may have the upper hand against nintedanib from Boehringer Ingelheim GmbH.

Earlier this year, both companies said their respective candidates for idiopathic pulmonary fibrosis (IPF) met the primary endpoint of improved forced vital capacity (FVC) vs. placebo in separate Phase III trials...